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Abstract
Background: Pancreatitis is the most common and serious complication to occur after endoscopic
retrograde cholangiopancreatography (ERCP). It is often associated with additional diagnostic modalities
and/or treatment of obstructive jaundice. The aim of this study was to determine the risk of post-ERCP
pancreatitis associated with pancreaticobiliary examination and endoscopic biliary drainage (EBD).
Methods: A total of 740 consecutive ERCP procedures performed in 477 patients were analysed for the
occurrence of pancreatitis. These included 470 EBD procedures and 167 procedures to further evaluate
the pancreaticobiliary tract using brush cytology and/or biopsy, intraductal ultrasound and/or peroral
cholangioscopy or peroral pancreatoscopy. The occurrence of post-ERCP pancreatitis was analysed
retrospectively.
Results: The overall incidence of post-ERCP pancreatitis was 3.9% (29 of 740 procedures). The risk
factors for post-ERCP pancreatitis were: being female (6.5%; odds ratio [OR] 2.5, P = 0.02); first EBD
procedure without endoscopic sphincterotomy (ES) (6.9%; OR 3.0, P = 0.003), and performing additional
diagnostic procedures on the pancreatobiliary duct (9.6%; OR 4.6, P < 0.0001). Pancreatitis after
subsequent draining procedures was rare (0.4%; OR for first-time drainage 16.6, P = 0.0003). Further-
more, pancreatitis was not recognized in 59 patients who underwent ES. Seven patients with post-EBD
pancreatitis were treated with additional ES.
Conclusions: Invasive diagnostic examinations of the pancreaticobiliary duct and first-time perampul-
lary biliary drainage without ES were high-risk factors for post-ERCP pancreatitis. Endoscopic sphinc-
terotomy may be of use to prevent post-EBD pancreatitis.
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Introduction
Pancreatitis is the most common and serious complication of
endoscopic retrograde cholangiopancreatography (ERCP), occur-
ring in 2%1 to 15%2 of cases according to criteria defined by
Cotton and others.3 Several technical and patient-related risk
factors for post-ERCP pancreatitis, which act independently or
together, have been identified.3–5 To date, clinicians have
attempted to minimize the incidence and severity of post-ERCP
pancreatitis by identifying high-risk populations,5 by making
devices to reduce the trauma caused by endoscopic interventions,
by administrating pharmacological agents,6–8 and by inserting
pancreatic stents after ERCP.9–11 Risk factors for the development
of post-ERCP pancreatitis include patient factors (female gen-
der,2,5 younger age,1,2 sphincter of Oddi dysfunction,2,5,12 cannula-
tion difficulty,2,12 pancreatic divisum,2 a history of post-ERCP
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pancreatitis2,12), operator factors (inexperienced operator, pro-
longed procedure time,12 repeated injection to pancreatic duct12)
and the role of additional procedures such as endoscopic sphinc-
terotomy (ES),2,12 precut papillotomy,1 endoscopic papillary
balloon dilatation (EPBD) and biliary stone extraction.1
Regardless of ES, endoscopic (retrograde) biliary drainage
(EBD), including EBD tube stent and endoscopic nasobiliary
drainage (ENBD) catheter placement, have been thought of as safe
and effective methods for treating acute cholangitis and obstruc-
tive jaundice13,14 in both benign15,16 and malignant disease.13 At
a recent international consensus conference of international
pancreaticobiliary experts held in Tokyo, about 90% of panellists
preferred endoscopic over percutaneous drainage approaches
and 24% of panellists felt that ES was not necessary for biliary
drainage.13
Thanks to the development of magnetic resonance cholangio-
pancreatography, the need for ERCP as a diagnostic procedure is
declining. However, ERCP is still a powerful tool17–19 for obtaining
samples for cytology and pathology19,20 andmay help to determine
the extent of the tumour prior to surgery using intraductal ultra-
sonography (IDUS)21,22 and by placing a small cholangiopan-
creatoscope (‘baby scope’).23,24 In this study, we retrospectively
determined the risk for post-ERCP pancreatitis, focusing particu-
larly on the incidence of pancreatitis after EBD insertion with or
without ES and after other invasive diagnostic procedures.
Materials and methods
Patients
Between October 2002 and August 2007, 447 patients (male : fe-
male ratio 295 : 152, mean age 65.3 years) underwent 740 ERCP-
associated procedures (male : female ratio 509:231) at Shizuoka
Cancer Centre. Of these 740 ERCPs, 525 procedures were carried
out in patients with invasive cancers (pancreatic ductal adenocar-
cinoma [296], biliary carcinoma [152; bile duct = 112, gallbladder
= 40], metastastic tumour with biliary obstruction [56], hepato-
cellular carcinoma [12], ampullary carcinoma [9]), 68 were per-
formed in patients with benign or intraductal neoplasms
(intraductal papillary mucinous neoplasm [IPMN] [46], ampul-
lary adenoma [15], pancreatic endocrine tumour [3], solid papil-
lary tumour [2], mucinous cystic neoplasm [MCN] [1], serous
cystadenoma [1]), and 147 were performed in patients with
benign inflammatory diseases, which included 73 procedures
carried out to remove bile duct stones. In the 12 cases with hepa-
tocellular carcinoma, six ERCP procedures were performed for
obstruction at the hepatic hilar bile duct, three for lower bile duct
obstruction caused by lymph nodal metastases, two for suspected
bile leak after hepatectomy, and one in a case with concurrent
sphincter of Oddi dysfunction. The ERCP procedures were indi-
cated for insertion or exchange of a plastic biliary stent in 470
cases (63.5%), and for invasive diagnostic examinations using at
least one of brush cytology, biopsy from pancreaticobiliary tract,
IDUS, peroral cholangioscopy (POCS) or peroral pancreatoscopy
(POPS) in 167 (22.6%). Endoscopic retrograde cholangiopancre-
atography was performed using Olympus endoscopes (JF240,
TJF240, JF260V), the PR109Q catheter for routine cannulation
and the Clever Cut 3V for ES (Olympus Corp., Tokyo, Japan).
Biliary drainage
Endoscopic biliary drainage was inserted or exchanged when the
patient had at least one symptom of Charcot’s triad (fever, jaun-
dice, abdominal pain), but was rarely performed in cases with only
mild hyperbilirubinaemia in order to maintain a constant level of
chemotherapy (consisting of chemo-agents metabolized through
the liver and biliary tract). The 470 biliary drainage procedures
consisted of 404 EBD and 66 ENBD procedures. For EBD, we used
a Tannenbaum plastic stent (8.5 and 10 Fr, 5 ~ 9 cm;Wilson-Cook
Medical Inc., Winston-Salem, NC, USA) in 86% of cases, a
Flexima® plastic stent (7.0 and 8.5 Fr, 10 ~ 12 cm: Boston Scien-
tific Corp., Natick, MA, USA) in 5% and a Zimmon plastic stent
(7 Fr, 7 ~ 10 cm;Wilson-Cook Medical Inc.) in the remaining 9%
of cases. For ENBD, we used a pigtailed NB tube (6 and 7 Fr;
Hanako Medical Co. Ltd, Saitama, Japan) in 97% of cases and a
pigtailed Liguory tube (5 Fr; Wilson-Cook Medical Inc.) in 3%.
We chose a thinner stent for the first insertion of a biliary drain
(8.5 Fr, 83% of procedures [203/245]), and a larger-diameter
stent for second and subsequent procedures (10 Fr, 61% of pro-
cedures [137/225 procedures]).
Diagnostic examination of the pancreaticobiliary tract
We categorized a procedure as a ‘diagnostic examination’when the
ERCP procedure included at least one of the following modalities:
endoscopic biopsy; brush cytology; IDUS; POCS, or POPS. The
indication for these invasive diagnostic examinations generally
referred to the need to establish a diagnosis of malignancy before
surgical operation.We used an FB44U-1 biopsy forceps (Olympus
Corp.) for duct biopsy, a BC-24Q (Olympus Corp.) endoscopic
brush catheter for brush cytology, a UM-G20-29R (Olympus
Corp.) for IDUS, a CHF-B260 (Olympus Corp.) for POCS, and a
PF Type 8P (Olympus Corp.) for POPS. When POCS was per-
formed, ES was always added. We did not include simple aspira-
tion cytology from the pancreaticobiliary duct because of the low
rate of pancreatitis. Of 167 procedures, 80 were biliary duct pro-
cedures, 69 involved the pancreatic duct and 18 involved both the
pancreatic and biliary tracts.
Criteria for the diagnosis of post-ERCP pancreatitis
Post-ERCP pancreatitis was diagnosed according to the generally
accepted criteria defined by Cotton et al.,3 (i.e. patients who had
upper abdominal pain 24 hours after an ERCP procedure and a
serum amylase level [U/l] more than three times the upper limit of
normal).
Data analysis
First, we examined 11 factors for the development of post-ERCP
pancreatitis, including seven factors identified in previous reports
(gender, age, biliary stone removal, performance of ES, EPBD,
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biliary metallic stent insertion and pancreatic plastic stent inser-
tion) and new factors (ERCP-associated diagnostic procedure,
EBD insertion [first-time and subsequent] and disease type).
These were analysed using chi-square test2 or Fisher’s test. Multi-
variate analysis using multiple logistic regression analysis was
added on the factors revealed to be significant by a single-variate
analysis to identify factors that were independently significant for
post-ERCP pancreatitis. Then, combinations of three significant
risk factors including initial EBD insertion, additional diagnostic
procedures and disease type were analysed by chi-square test2 or
Fisher’s test. A P-value of < 0.05 was considered as statistically
significant.
Results
Risk factors of post-ERCP pancreatitis
Post-ERCP pancreatitis occurred in 29 of 740 (3.9%) ERCP
procedures. Ten risk factors for the development of post-ERCP
pancreatitis are summarized in Table 1. Invasive diagnostic exami-
nation (biopsy, brush cytology, IDUS and baby scope observa-
tion), first-time biliary drainage, being female and the presence of
particular disease types (pancreatic tumour other than pancreatic
carcinoma including IPMN, MCN, solid-cystic tumour) were
evaluated as statistically significant by single-variate analysis. The
odds ratio (OR) for developing post-ERCP pancreatitis as a result
of pancreaticobiliary invasive examination was 4.6, of first-time
biliary drainage 3.0, of pancreatic tumour other than pancreatic
carcinoma 2.9 and of female gender 2.5. Although the P-value was
0.0502, the group with non-neoplastic pancreaticobiliary disease
without bile duct stone removal showed a higher trend of post-
ERCP pancreatitis (OR 2.5) (Table 1). The six risk factors listed
above were further analysed by multivariate analysis and the result
showed independent risk for post-ERCP pancreatitis for first-time
EBD (r = 3.44), diagnostic examination (r = 2.98), being female (r
= 2.47) and benign pancreatic tumour (r = 2.15) (Table 2). Most
ERCP procedures were performed by two experienced endosco-
pists (HM and AF had each carried out >1000 ERCP-associated
procedures) and the incidence of post-ERCP pancreatitis did not
differ by operator. All pancreatitis cases were graded as mild and
recovery required only a couple of days of hospitalization with i.v.
analgesia and i.v. fluids.
Risk for pancreatitis after endoscopic biliary drainage
Post-EBD pancreatitis occurred in 17 of 246 (6.9%) patients
undergoing biliary drainage for the first time, despite the fact that
most stents were small-bore (8.5 Fr in 83% of cases). There was
a trend for post-ERCP pancreatitis to be more common when
larger-bore (8.5 Fr) stents were used (7.4% [14/189] of cases,
including 7.3% [3/41] of 10-Fr cases and 7.4% [11/148] of 8.5-Fr
cases) than when stents <8.5 Fr were used (5.3% [3/57] of cases).
As Table 3 shows, performing additional invasive examinations on
first-time drainage increased the incidence up to three times
(15.2% vs. 5.0%; OR 3.4, P = 0.01). However, pancreatitis did not
occur after sphincterotomy (none of 17 cases). Post-EBD pancre-
atitis often occurred in cases with small papilla or narrow papilla
apertures that impeded the smooth insertion of the drainage tube.
Risk of pancreatitis after ERCP-associated
diagnostic examination
We recognized pancreatitis in 9.6% of subjects who underwent
ERCP-associated diagnostic examination using at least one addi-
tional diagnostic modality (biopsy, brush cytology, IDUS, POCS
or POPS) with an OR of 4.6 (P < 0.0001) (Table 1). As shown in
Table 4, when the first EBD was added after these diagnostic
examinations, the risk of pancreatitis increased 2.2 times (P =
0.13).When we applied multiple modalities, the incidence of pan-
creatitis increased modestly but not significantly. The incidence of
post-ERCP pancreatitis did not differ by site of lesion or diagnos-
tic modality (Table 4).
Risk of post-ERCP pancreatitis by disease type
As Table 5 shows, the incidence of post-ERCP pancreatitis varied
by disease type.
The incidence of post-ERCP pancreatitis was high in patients
with benign pancreatic tumours other than pancreatic carcinoma
(9.4%, five of 53 cases), those with benign pancreaticobiliary
disease except for bile duct stone (8.1%, six of 74 cases) and biliary
carcinoma (5.9%, nine of 152 cases), and lower than average in
patients with pancreatic adenocarcinoma (2.4%, seven of 296
cases) and those with metastatic cancers with biliary obstruction
(3.6%, two of 56 cases). There was a significant difference in the
incidence of pancreatitis in patients with pancreatic tumours
other than pancreatic carcinoma compared with those with pan-
creatic adenocarcinoma (P = 0.009) and between patients with
benign pancreaticobiliary disease and those with pancreatic
adenocarcinoma (P = 0.016). In cases of first-time EBD insertion,
subjects with biliary carcinoma (17.0%) showed a higher inci-
dence of post-EBD pancreatitis than those with pancreatic adeno-
carcinoma (4.2%) (P = 0.005). Similarly, by adding other risk
factors, the incidence of post-ERCP pancreatitis increased, for
instance, up to 27.3% (six of 22) in biliary carcinoma cases with
first-time EBD and diagnostic examination (Table 5).
Post-ERCP pancreatitis after ES and ES for
post-EBD pancreatitis
As Table 1 shows, whether with or without EBD, none of the 59
patients who underwent ES procedures and none of 17 cases with
pancreatic stent insertion developed pancreatitis. In cases of initial
EBD without ES, seven patients who developed post-EBD pan-
creatitis were treated with additional ES to facilitate pancreatic
drainage, including one subject who was treated further with the
placement of a smaller EBD instrument and another with the
placement of a pancreatic stent. These procedures were associated
with a decrease in abdominal pain and improved serum amylase
levels.
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Discussion
We have identified four risk factors for the development of
post-ERCP pancreatitis: being female; first-time EBD com-
pared with subsequent EBD procedures; the performance of
additional invasive diagnostic examinations associated with
ERCP, and the underlying disease (benign pancreatic
tumours).
Table 1 Incidence and risk level of post-endoscopic retrograde cholangiopancreatography pancreatitis (n = 740 procedures)
Factor Frequency of post-ERCP
pancreatitis (n)
Odds ratio P-valuea
Significant
Diagnostic examinationb (+) 9.6% (16/167) 4.6 <0.0001
(-) 2.3% (13/573)
First EBD (+) 6.9% (17/246) 3.0 0.003
(-) 2.4% (12/494)
Gender Female 6.5% (15/231) 2.5 0.02
Male 2.8% (14/509)
Disease Neoplasm 3.9% (23/593) 0.9 0.95
Non-neoplasm 4.1% (6/147)
Pancreatic carcinoma 2.4% (7/296) 0.5 0.08
Biliary carcinomac 5.9% (9/152) 1.8 0.15
Obstructive jaundice by distant metastasis 3.6% (2/56) 0.9 0.89
HCC 0% (0/12) – 0.48
Pancreatic tumour other than pancreatic carcinoma 9.4% (5/53)d 2.9 0.03
Ampullary tumoure 0% (0/24) – 0.31
Bile duct stone 0% (0/73) – 0.07
Non-neoplastic pancreaticobiliary diseasef 8.1% (6/74) 2.5 0.0502
Not significant
ES (+) 0% (0/59) – 0.11
(-) 4.3% (29/681)
Stone removal (+) 0% (0/44) – 0.17
(-) 4.2% (29/696)
EPBD (+) 0% (0/24) – 0.31
(-) 4.1% (29/716)
Pancreatic stent (+) 0% (0/17) – 0.40
(-) 4.0% (29/723)
Biliary metallic stent (+) 0% (0/14) – 0.45
(-) 4.0% (29/726)
Overall EBD (+) 3.8% (18/470) 0.9 0.90
(-) 4.1% (11/270)
Age, years >65 4.0% (15/378) 1.0 0.94
65 3.9% (14/362)
Overall 3.9% (29/740)
aChi-square test, Fisher's test
bDiagnostic examination of pancreatobiliary duct included at least one of biopsy, brush cytology, intraductal ultrasound, peroral cholangioscopy and
peroral pancreatoscopy
cBiliary carcinomas included 42 cases of bile duct carcinoma and 11 cases of gallbladder carcinoma
dPost-ERCP pancreatitis was recognized in 6.5% (6/46) of cases with intraductal papillary mucinous neoplasm, one of two cases with solid-cystic
tumour, one case of serous cyst adenoma and none of three pancreatic endocrine tumours and one mucinous cystic neoplasm
eAmpullary tumours included nine cases of carcinoma and 15 cases of adenoma
fBenign pancreaticobiliary inflammatory disease included benign biliary and pancreatic duct stricture, pancreatic cyst, chronic pancreatitis, chole-
cystitis and gallstone, except for cases with bile duct stone
ERCP, endoscopic retrograde cholangiopancreatography; EBD, endoscopic biliary drainage; HCC, hepatocellular carcinoma; ES, endoscopic
sphincterotomy; EPBD, endoscopic papillary balloon dilatation
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Our results suggest that the first EBD procedure is riskier than
subsequent procedures, especially when the drainage instrument
is thicker (8.5 Fr); by contrast, no pancreatitis was observed and
post-EBD pancreatitis recovered when biliary ES was added. To
date, the first EBD procedure has not been reported as a risk for
post-ERCP pancreatitis.1,15 Hui et al.15 reported that the risk of
pancreatitis did not depend on whether or not an ES was per-
formed before EBD insertion; however, these authors used a small
(7 Fr) stent.Multicentre analysis in Italy also showed no difference
in occurrences of pancreatitis with and without EBD insertion (P
= 0.12). Of note, more than two-thirds of ERCP procedures for
biliary drainage in this study (1662 of 2444) were carried out with
ES. At a consensus meeting in Tokyo in 2006,13 more than two-
thirds of international experts agreed on the necessity of ES for
EBD insertion in certain situations despite the known complica-
tions of ES, which include haemorrhage and pancreatitis.25–27 In
our experience of initial EBD insertion, post-EBD pancreatitis is
frequently observed when there is resistance against stent inser-
Table 2 Risk for post-endoscopic retrograde cholangiopancreatography pancreatitis by multivariate analysis (n = 740 procedures)
Factor R P-value 95% CI
First EBD 3.44 0.0006 1.98 ~ 12.16
Diagnostic examination, n 2.98 0.003 1.56 ~ 8.63
Female 2.47 0.013 1.23 ~ 5.90
Benign pancreatic tumour other than pancreatic cancer 2.15 0.032 1.13 ~ 15.46
Non-neoplastic pancreaticobiliary diseasea 1.82 0.069 0.93 ~ 7.88
aNon-neoplastic pancreaticobiliary disease except for 73 cases of biliary stone
95% CI, 95% confidence interval; EBD, endoscopic biliary drainage
Table 3 Risk factors for post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis in cases of first-time endoscopic biliary
drainage (n = 246 cases)
Factor Frequency of post-ERCP pancreatitis (n) Odds ratio P-valuea
Diagnostic examination (+) 15.2% (7/46) 3.4 0.01
(-) 5.0% (10/200)
Endoscopic sphincterotomy (+) 0% (0/17) – 0.24
(-) 7.4% (17/229)
Size of drain 8.5 Fr 7.4% (14/189) 1.4 0.58
<8.5 Fr 5.3% (3/57)
aChi-square test, Fisher's test
Table 4 Risk factors for post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis in cases with pancreatobiliary diagnos-
tic examination (n = 167 procedures)
Factor Frequency of post-ERCP pancreatitis (n) Odds ratio P-valuea
First-time biliary drainage (+) 15.2% (7/46) 2.2 0.13
(-) 7.4% (9/121)
Target region Biliary duct 10.0% (8/80) – 0.83
Pancreatic duct 10.1% (7/69)
Both 5.6% (1/18)
Number of modalities per case 1 8.2% (4/49) – 0.88
2 8.9% (5/56)
3 9.8% (4/41)
4 14.3% (3/21)
Modality Biopsy 10.1% (11/109) – 0.90
Brush cytology 9.0% (10/111)
IDUS 11.9% (12/101)
POCS or POPS 12.0% (3/25)
aChi-square test, Fisher's test
ERCP, endoscopic retrograde cholangiopancreatography; IDUS, intraductal ultrasound; POCS, peroral cholangioscopy; POPS, peroral
pancreatoscopy
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tion through a relatively small papillary orifice (data not shown),
presumably because of the tight obstruction of the ampullary
pancreatic duct by the biliary drainage. This impression is sup-
ported by data showing that the incidence of post-ERCP pancre-
atitis was significantly higher after a first drainage procedure
(6.9%, 17 of 246 procedures) than after the second (0.5%, one of
224 procedures). More than 80% of EBD procedures were per-
formed using stents of 8.5 Fr for initial drainage. These data
thus highlight the fact that pancreatitis is not uncommon after
EBD, even when small-bore stents (<8.5 Fr) are used.
Another risk factor for the development of post-ERCP pancre-
atitis is the performance of additional ‘invasive diagnostic proce-
dures’ including biopsy, brush cytology, IDUS and the use of a
baby scope. In our series, the incidence of pancreatitis was higher
in patients who underwent many diagnostic procedures, espe-
cially when a procedure followed EBD insertion. It is noteworthy
that post-ERCP pancreatitis was higher in patients with biliary
adenocarcinoma, benign pancreatic tumours and non-neoplastic
pancreaticobiliary diseases than in those with pancreatic adeno-
carcinoma. This trend was remarkable when initial biliary drain-
age was added (Table 4) and in cases of biliary carcinoma or
benign non-neoplastic pancreaticobiliary disease (Table 5). Many
pancreatic cancers have already caused obstruction of the main
pancreatic duct and accompanying chronic pancreatitis of the
upstream pancreas at the time of clinical presentation. It is quite
possible that acute pancreatitis after ERCP is less likely in a chroni-
cally scarred gland that has severe fibrosis and atrophy. As many
pancreaticobiliary duct neoplasms are accompanied by obstructed
jaundice, one of the techniques by which post-EBD pancreatitis
can be avoided involves improving pancreatic juice drainage by
performing a biliary sphincterotomy when the papillary orifice is
small.
To date, many risk factors for post-ERCP pancreatitis have been
reported from high-volume centres, such as being female,2,5 being
of younger age,1,2 sphincter of Oddi dysfunction,2,5,12 cannulation
difficulty,2,12 prolonged procedure time,12 repeated injection to the
pancreatic duct,12 precut papillotomy,1 EPBD and biliary stone
extraction.1 Our result was not fully consistent with these,
however, and we must remember that not many of these factors
were analysed in our study and that the major proportion of our
study population consisted of cases with neoplasm. Further pro-
spective study is needed to confirm the current postulations.
Endoscopists should be aware of the risk of pancreatitis when
they perform additional invasive diagnostic examinations and/or
first-time perampullary biliary drainage associated with ERCP,
depending on the disease type. Recent reports have demonstrated
the effects of guidewire cannulation28,29 and pancreatic stent inser-
tion9,10 in the prevention of post-ERCP pancreatitis. Given the
current results, minimizing the number of invasive diagnostic
modalities and adding ES may also be effective in preventing
post-ERCP and post-EBD pancreatitis.
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